ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,260.09
1.07%
Dow Jones
42,392.27
-0.36%
Gold vs US Dollar
2,661.03
0.10%
Brent Oil
75.855
0.00%
Bitcoin
96,945.41
0.05%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Werewolf Therapeutics Inc (HOWL) Share Price

HOWL Werewolf Therapeutics Inc

1.56
0.08 (5.41%)
After Hours
Last Updated: 22:01:54
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Werewolf Therapeutics Inc NASDAQ:HOWL NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.08 5.41 1.56 1.54 1.56 1.63 1.505 1.51 348,209 22:01:54   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 19.94M -37.37M -0.8385 -1.85 65.95M
 Type  Size  Price  Time  Units 
 9 1 1.56 23:33:37 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore HOWL News
20/11/202413:00GLOBEWerewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
07/11/202414:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202414:06EDGAR2Form 8-K - Current report
07/11/202414:02GLOBEWerewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
07/11/202414:00GLOBEWerewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
31/10/202412:00GLOBEWerewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
04/10/202413:00GLOBEWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Period
Draw mode
Data Downloads for HOWL

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Werewolf Therapeutics Inc Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads